Pill Identifier App

Generic Teflaro Availability

Teflaro is a brand name of ceftaroline, approved by the FDA in the following formulation(s):

TEFLARO (ceftaroline fosamil - powder;iv (infusion))

  • Manufacturer: CEREXA
    Approval date: October 29, 2010
    Strength(s): 400MG/VIAL, 600MG/VIAL [RLD]

Has a generic version of Teflaro been approved?

No. There is currently no therapeutically equivalent version of Teflaro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Teflaro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Phosphonocephem derivatives, process for the preparation of the same, and use thereof
    Patent 6,417,175
    Issued: July 9, 2002
    Inventor(s): Tomoyasu; Ishikawa & Shohei; Hashiguchi & Yuji; Iizawa
    Assignee(s): Takeda Chemical Industries, Ltd.
    A novel cephem compound of the formula: wherein R1 is a phosphono group or a group convertible to a phosphono group; R2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH2; n is 0 or 1; one of R3 and R4 is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R3 and R4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, or its ester or its salt, which has a superior anti-bacterial activity, stability, absorbability, etc., a production thereof and a pharmaceutical composition containing it, is provided.
    Patent expiration dates:
    • December 17, 2018
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Phosphonocephem compound
    Patent 6,906,055
    Issued: June 14, 2005
    Inventor(s): Ishikawa; Tomoyasu & Hashiguchi; Shohei & Iizawa; Yuji
    Assignee(s): Takeda Chemical Industries, Ltd.
    A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like.
    Patent expiration dates:
    • December 15, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Phosphonocephem compound
    Patent 7,419,973
    Issued: September 2, 2008
    Inventor(s): Ishikawa; Tomoyasu & Hashiguchi; Shohei & Iizawa; Yuji
    Assignee(s): Takeda Pharmaceutical Company Limited
    A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like.
    Patent expiration dates:
    • December 15, 2021
      ✓ 
      Drug product
  • Cephem compounds useful for the treatment of bacterial infections
    Patent 8,247,400
    Issued: August 21, 2012
    Inventor(s): Dedhiya; Mahendra G. & Singh; Brahma N.
    The present invention relates to new cephem compounds useful for the treatment of bacterial infections of formula I: The invention also relates to methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and to methods of treatment using the compounds. The new cephem compounds are stable, exhibit good solubility, and are particularly well suited for, e.g., parenteral administration for the treatment of bacterial infections.
    Patent expiration dates:
    • February 10, 2031
      ✓ 
      Patent use: METHOD OF TREATING BACTERIAL INFECTIONS
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 29, 2015 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)